002675.SZ
东诚药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.77
−2.07%Year over year
Reported trailing growth
- Revenue
- -7.8%
- EBITDA
- —
- EBIT
- +31.3%
- EPS
- +41.6%
- Free cash flow
- -50.9%
- Operating cash flow
- -23.3%
Forward estimates
Based on analyst estimates
- Revenue
- +0.0%
- EBITDA
- +128.9%
- EPS
- +85.7%
Three-year CAGR
- Revenue
- -8.5%
- EBITDA
- -10.3%
- EBIT
- -22.0%
- Net income
- -14.0%
- EPS
- -14.6%
- Free cash flow
- -28.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026